Neuronetics (NASDAQ: STIM) has named Steven Pfanstiel its new chief financial officer, succeeding Steve Furlong, who will retire in March 2026 and remain as senior adviser through the transition.
Pfanstiel previously served as CFO and COO at Marinus Pharmaceuticals, where he helped launch the anti-seizure therapy Ztalmy and oversaw Marinus’ sale to Immedica Pharma. His background also includes senior finance roles at Lifescan, Optinose and Johnson & Johnson.
CEO Keith Sullivan credited Furlong with strengthening Neuronetics’ finances and guiding its acquisition of Greenbrook. Pfanstiel said he aims to help expand the reach of Neuronetics’ NeuroStar TMS therapy and its Greenbrook clinic network to support more patients with mental health conditions.
Follow MEDWIRE.AI for mental health technology leadership updates.
